ESR1 and breast carcinoma: Concurrent IHC staining for Ki67, a marker of proliferation [25], showed much higher percentage of Ki67+ cells in ADA3 high PDX sample vs. the ADA3 intermediate sample (Additional file 1: Figure S1), prompting further analyses using tissue microarrays derived from a large cohort of ER+ breast cancer patients.